Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H C Lane

Showing results (181-190 of 209) with videos related to

Pageof 21
Sort By:
The Journal of Infectious Diseases|March 14, 1998
Progression of human immunodeficiency virus disease is associated with increasing disruptions within the CD4+ T cell receptor repertoireJ C Gea-Banacloche, E E Weiskopf, C Hallahan, et al.
Science (New York, N.Y.)|September 7, 2019
Evaluation of an antibody to α<sub>4</sub>β<sub>7</sub> in the control of SIVmac239-<i>nef-stop</i> infectionM Di Mascio, J D Lifson, S Srinivasula, et al.
Pharmacotherapy|December 28, 1999
Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction studyJ Falloon, S Sargent, S C Piscitelli, et al.
The New England Journal of Medicine|October 31, 1996
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virusJ A Kovacs, S Vogel, J M Albert, et al.
The Journal of Infectious Diseases|April 1, 1997
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected personsR T Davey, D G Chaitt, S C Piscitelli, et al.
Clinical Immunology (Orlando, Fla.)|April 5, 2001
Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansionK D Miller, K Spooner, B R Herpin, et al.
Nature Medicine|May 1, 1997
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapiesM Connors, J A Kovacs, S Krevat, et al.
AIDS (London, England)|January 11, 2000
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in ThailandK Ruxrungtham, S Suwanagool, J A Tavel, et al.
The Journal of Infectious Diseases|March 18, 2006
Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected personsR A Lempicki, M A Polis, J Yang, et al.
The Journal of Infectious Diseases|July 1, 1996
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1R E Walker, K M Spooner, G Kelly, et al.
Pageof 21

Showing results (181-190 of 209) with videos related to

Sort By:
Pageof 21
The Journal of Infectious Diseases|March 14, 1998
Progression of human immunodeficiency virus disease is associated with increasing disruptions within the CD4+ T cell receptor repertoireJ C Gea-Banacloche, E E Weiskopf, C Hallahan, et al.
Science (New York, N.Y.)|September 7, 2019
Evaluation of an antibody to α<sub>4</sub>β<sub>7</sub> in the control of SIVmac239-<i>nef-stop</i> infectionM Di Mascio, J D Lifson, S Srinivasula, et al.
Pharmacotherapy|December 28, 1999
Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction studyJ Falloon, S Sargent, S C Piscitelli, et al.
The New England Journal of Medicine|October 31, 1996
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virusJ A Kovacs, S Vogel, J M Albert, et al.
The Journal of Infectious Diseases|April 1, 1997
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected personsR T Davey, D G Chaitt, S C Piscitelli, et al.
Clinical Immunology (Orlando, Fla.)|April 5, 2001
Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansionK D Miller, K Spooner, B R Herpin, et al.
Nature Medicine|May 1, 1997
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapiesM Connors, J A Kovacs, S Krevat, et al.
AIDS (London, England)|January 11, 2000
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in ThailandK Ruxrungtham, S Suwanagool, J A Tavel, et al.
The Journal of Infectious Diseases|March 18, 2006
Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected personsR A Lempicki, M A Polis, J Yang, et al.
The Journal of Infectious Diseases|July 1, 1996
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1R E Walker, K M Spooner, G Kelly, et al.
Pageof 21